152918-47-3

Basic information

• Product Name: 1-(6-Chloro-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-isopropylidene-beta-D-ribofuranuronamide
• Synonyms: 1-(6-Chloro-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-isopropylidene-beta-D-ribofuranuronamide;2',3'-O-isopropylidene-6-chloropurine-5'-N-MethyluronaMide;2',3'-isopropylidene-1-(6-chloro-9H-purin-9-yl)-1-deoxy-N-methyl-β-D-ribofuranosiduronamide
• CAS NO: 152918-47-3
• Molecular Formula: C₁₄H₁₆ClN₅O₄
• Molecular Weight: 353.76094
• Mol File: 152918-47-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.74
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(6-Chloro-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-isopropylidene-beta-D-ribofuranuronamide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-Chloro-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-isopropylidene-beta-D-ribofuranuronamide(152918-47-3)
• EPA Substance Registry System: 1-(6-Chloro-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-isopropylidene-beta-D-ribofuranuronamide(152918-47-3)

Safety Data

• Hazardous Substances Data: 152918-47-3(Hazardous Substances Data)

Usage

General Description

1-(6-Chloro-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-isopropylidene-beta-D-ribofuranuronamide, also known as clade 9-CMP, is a chemical compound containing a purine base with a methyl group and a ribofuranuronamide moiety. It is an important intermediate in the synthesis of nucleoside analogs and derivatives, and it has been studied for its potential pharmaceutical applications, particularly in the development of antiviral and anticancer drugs. 1-(6-Chloro-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-isopropylidene-beta-D-ribofuranuronamide has demonstrated biological activity in inhibiting viral replication, and it has also shown promise as a cytotoxic agent against cancer cells. Its unique structure and potential therapeutic properties make it an interesting target for further research and development in medicinal chemistry.

Upstream product

• 120355-42-2 (3AS,4S,6R,6AR)-6-(6-chloro-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid 
• 74-89-5 methylamine 
• 39824-26-5 6-chloro-9-(2,3-O-isopropylidene-β-D-ribofuranosyl)-9H-purine 
• 2004-06-0 6-Chloropurine riboside 
• 28440-13-3 (3aS,4S,6R,6aR)-2,2-dimethyl-6-(6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid 
• 2140-11-6 2',3'-O-isopropylideneinosine 
• 104940-65-0 1'-deoxy-1'-(6-chloro-9H-purin-9-yl)2',3'-O-isopropylidene-β-D-ribofuranosyl chloride 

Downstream Products

• 1053243-75-6 (3aS,4S,6R,6aR)-6-[6-(4-Bromo-benzylamino)-purin-9-yl]-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid methylamide 
• 152918-15-5 NNC 21-0242 
• 152918-20-2 Abamun 
• 152918-26-8 [125I]-AB-MECA 
• 152918-18-8 N⁶-(3-iodobenzyl)adenosine-5'-N-methyluronamide 
• 152918-27-9 (2S,3S,4R,5R)-5-[6-(4-Amino-3-iodo-benzylamino)-purin-9-yl]-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid methylamide 
• 152918-53-1 (3aS,4S,6R,6aR)-6-[6-(3-Acetylamino-benzylamino)-purin-9-yl]-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid methylamide 
• 152918-48-4 IB-MECA acetonide 
• 1054620-26-6 (3aS,4S,6R,6aR)-6-(6-{2-[1-(2,5-Dimethyl-benzyl)-1H-indol-3-yl]-ethylamino}-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid methylamide 
• 1053645-63-8 (3aS,4S,6R,6aR)-6-(6-Benzylamino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid methylamide 
• 1053726-11-6 (3aS,4S,6R,6aR)-6-[6-(4-Amino-3-iodo-benzylamino)-purin-9-yl]-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid methylamide 

Relevant articles and documents

PROCESS FOR THE SYNTHESIS OF IB-MECA

The present disclosure provides a method for the synthesis of IB-MECA. More specifically, the present disclosure provides a simple and high yield method for Good Manufacturing Production (GMP) of IB-MECA. The method involves the reaction of 6-halopurine-9

N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.

The coronary vasoactivity of N-ethyl-1'-deoxy-1'-(6-amino-9H-purin-9-yl)-beta-D-ribofuranuronamide (NECA, 1) is over 2 orders of magnitude greater than that of adenosine, and the vasoactivity of certain N6-substituted adenosines is as much as 1 order of m